ETX101 for epilepsies, myoclonic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 1 Nov 2023: Trial registered, NCT06112275
  2. 28 Feb 2024: Trial started, NCT06112275
  3. 28 Feb 2024: Trial registered, NCT06283212
  4. 9 May 2024: Trial started, NCT06283212

The trials

NCT06112275: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

State
Under way
Phase
Phase 1 and Phase 2
People
4 taking part
Started
28 Feb 2024
Primary completion
Sep 2030
Arms
Cohort A, Cohort B, Cohort C, Cohort D
Results
None posted
  1. 1 Nov 2023: Trial registered
  2. 28 Feb 2024: Trial started

NCT06283212: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

State
Under way
Phase
Phase 1 and Phase 2
People
5 taking part
Started
9 May 2024
Primary completion
Oct 2030
Arms
Cohort A, Cohort B, Cohort C, Cohort D
Results
None posted
  1. 28 Feb 2024: Trial registered
  2. 9 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.